Home  >  News
you can get e-magazine links on WhatsApp.Click here
Pioma_Lactic
Research + Font Resize -

SpeeDx expands product line of research reagents for Covid-19 variant analysis to include SARS-CoV-2 Lambda VOI

Sydney
Thursday, October 7, 2021, 09:00 Hrs  [IST]

SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, have further expanded their product line of research reagents for Covid-19 variant analysis to include a key characteristic mutation connected to the SARS-CoV-2 Lambda variant of interest (VOI).

The PlexPrime SARS-CoV-2 Genotyping product line has rapidly expanded since launching in July, utilising the company’s unique universal substrate approach and patented multiplexing technology. The suite of products can be used independently or combined to support laboratory investigation and monitoring efforts of key SARS-CoV-2 variants of interest or concern.

“Rapid screening of positive samples with a PCR-based approach allows laboratories to easily monitor mutations as they circulate” said Dr Charles Cartwright, SpeeDx senior vice president of clinical affairs. “The individual mutations targeted with our suite of genotyping reagents have been carefully chosen to represent key lineage divergence, thus we are finding that even the latest emerging variants of interest and concern can be targeted for further analysis with our existing portfolio.”

PlexPrime SARS-CoV-2 L452Q Lambda is a single well mix designed to detect the L452Q spike mutation of SARS-CoV-2 found in the C.37 variant of interest (Lambda), in addition to an RdRp gene target of SARS-CoV-2. This reagent is the third product in the PlexPrime SARS-CoV-2 Genotyping portfolio and can be used as a stand-alone reflex or combined with PlexPrime SARS-CoV-2 Alpha/Beta/Gamma+, and/or the PlexPrime P681R Delta reagents. Compatible with standard qPCR and liquid handling instrumentation, the PlexPrime® SARS-CoV-2 Genotyping will reduce the costs and manual processes for laboratories currently practicing high-volume sequence analysis.

Founded in 2009, SpeeDx is an Australian-based private company with subsidiary offices in Austin and London, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management.

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |